The earlier, the better? A review of neoadjuvant immunotherapy in resectable non-small-cell lung cancer
- VernacularTitle:The earlier, the better? A review of neoadjuvant immunotherapy in resectable non-small-cell lung cancer
- Author:
Fajiu LI
1
;
Ying CHEN
;
Juanjuan WU
;
Chenghong LI
;
Shi CHEN
;
Ziyang ZHU
;
Wei QIN
;
Min LIU
;
Bingzhu HU
;
Shuang LIU
;
Wenzhao ZHONG
Author Information
- Publication Type:Journal Article
- Keywords: immune checkpoint inhibitors; neoadjuvant treatment; non-small-cell lung cancer
- From: Chronic Diseases and Translational Medicine 2022;08(2):100-111
- CountryChina
- Language:English
- Abstract: Immune checkpoint inhibitors (ICIs) have revolutionized the approach to advanced and locally advanced non-small-cell lung cancer (NSCLC). Antibodies blocking inhibitory immune checkpoints, such as programmed death 1 (PD-1) and its ligand (PD-L1), have remarkable antitumor efficacy and have been approved as a standard first- or second-line treatment in non-oncogene-addicted advanced NSCLC. The successful application of immunotherapy in advanced lung cancer has motivated researchers to further evaluate its clinical role as a neoadjuvant setting for resectable NSCLC and for improved long-term overall survival and curative rates. In this review, we discuss the efforts that incorporate ICIs into the treatment paradigm for surgically resectable lung cancer. We reviewed the early-phase results from neoadjuvant clinical trials, the landscape of the majority of ongoing phase III trials, and discuss the prospects of ICIs as a curative therapy for resectable lung cancer. We also summarized the potential biomarkers and beneficiaries involved in the current study, as well as the remaining unresolved challenges for neoadjuvant immunotherapy.
